Latest Commercialization News

Fleetwood Limited delivered a robust FY25 performance with significant earnings growth and a strong dividend increase, while outlining a confident outlook for FY26 despite challenges in its RV Solutions segment.

First Graphene Limited’s partnership with Halocell Energy and QUT has yielded a breakthrough in perovskite solar cells, doubling efficiency to 30.6% while cutting production costs by up to 80%. This innovation paves the way for scalable, low-cost solar solutions across multiple industries.

Terragen Holdings reported a $3.72 million loss for FY25, impacted by drought and lower revenues, while launching dry probiotic products targeting feedlots and completing a $4.76 million equity raise.

Winton Land Limited reported a 10.5% revenue decline to NZD 155.4 million for FY25, with net profit after tax down 34.4%, as subdued Auckland markets and economic headwinds persist. The company is focusing on South Island developments and Fast-track approvals to navigate the downturn.

Cleo Diagnostics reported a $4 million loss for FY2025 while making significant strides toward FDA approval of its novel ovarian cancer blood test. The company is progressing clinical trials and scaling manufacturing in preparation for market entry.

CVC Limited reports a stable FY2025 profit alongside a robust landbank poised for significant value uplift, targeting a net tangible asset per share of $5.75 through strategic rezoning and development.

Hazer Group has reported a remarkable FY25 performance with revenues more than doubling and losses slashed by 60%, underpinned by a strategic partnership with KBR and early commercial revenues.

Hazer Group Limited reported a 124% surge in revenues to $8.5 million for FY25, driven by government grants, while cutting its net loss by 60%. The company advanced its proprietary methane pyrolysis technology, secured a strategic alliance with KBR, and made progress on key projects in Canada and Japan.

Elanor Commercial Property Fund reported a statutory loss for FY25 but delivered a 6.9% rise in Funds from Operations, while rejecting an unsolicited takeover offer from the Lederer Group.

Starpharma reports a significant 183% jump in FY25 revenue to $4.9 million, alongside a 31% reduction in losses and a solid cash position of $15.4 million. The biotech firm’s progress underscores growing momentum in its dendrimer technology pipeline.

Elanor Commercial Property Fund reported a solid FY25 with strong income and portfolio stability, while rejecting an unsolicited takeover bid from Lederer Group.

Elanor Commercial Property Fund has met its FY25 earnings guidance with robust leasing activity and a strong occupancy rate, setting a stable foundation for FY26 despite market headwinds.